Admittedly, my statement is not quite true. You would most assuredly assert that the 25 to 30 PE necessarily already includes all of those possiblities. In which case, I would say not so. No Biotechs really trade on EPS since there are little to none. It is all about new creations to help mankind and the commensurate possibilities to make a difference.
at the moment i see reports showing anywhere between 59% and 75% institutional ownership. I wonder what kind of pressure they are putting on management to ACT. Ultimately I believe if they do not act, they should be ousted
rally so they can portray strength and unity.
This correction is over. We now go into the football season and all eyes will be on fantasy football leagues, grilling and tailgating, plus Labor Day holiday.
Everyone I know is traveling somewhere.
Fliegerfaust site not working?what does this mean you might ask? it might mean bbd severed its ties with blain?,since fliegerfaust is a subsidiary of blain capital...c hub operated by bbd p.r. is however operational..
Adopting Mantle is not an option! Do it right, or you will not be DX12 ready..lol. Bashers say mantle will not ne adopted..Ho Ho HO!
Haha, or maybe he sniffed the glue that holds the sole onto the shoe one too many times.
NVAX vaccines are NOT DESIGNED to provide Cross-Strain Protection against KNOWN & New UNMATCHED viruses ( handle MUTATION ), if I am not mistaken.
I did a lot of reading this evening on NVAX's vaccine design process to respond to your comment. And, I could not find anywhere in NVAX's website that its MERS vaccine is designed to handle mutating strains of viruses.
From my understanding,
the way NVAX handles mutation is by developing newly formulated vaccines for the newly mutated viruses QUICKER than conventional vaccine platform.
( But, once the virus strain mutates again, its vaccines are useless again. Basically, NVAX needs to re-formulate another vaccine every time the virus mutates. The advantage of NVAX's vaccine platform is that it can do the catching up of mutations quicker than conventional vaccine technology. )
INOVIO's Vaccine Design Process is NIGHT & DAY different from NVAX's Vaccine platform, imo.
INO can formulate ONE VACCINE per disease that can handle mutations of multiple strains of viruses ( One vaccine can provide Cross-Strain Protection against KNOWN & NEW UNMATCHED viruses. NO catching up needed ).
Even NVAX's "Quadrivalent Flu Vaccine" only protects against 4 strains of the virus.
There are possibility of THOUSANDS of STRAINS of influenza virus ( trying to match 4 out of 1,000s seem daunting, imo ).
INOVIO's "UNIVERSAL Influenza Vaccine" in Phase 1 Human Clinical Trial demonstrated immune responses against SIX ( 6 ) UNMATCHED H5N1 strains as well a the NINE ( 9 ) key H1N1 flu strains of the past 100 years, including the 1918 pandemic flu.
Google search & Watch this video :
( " Q&A, Inovio CEO on DNA Vaccine, Digits, WSJ " )
#1 what everyone on this board will do on your grave,
#2 the steaming pile of it you are!
Goodbrain, I was referencing Colton as the simpleton. I respect your insights. I was on the same page with you with OREX when it had the spike a few weeks ago. Good trade for you and I.
Looking for a new position on Monday.
Sentiment: Strong Buy
Was pud trying to say that mass changes just like weight depending on where it was measured and by whom was doing the measurement? How can that be given that mass is a measurement of how much "stuff" is in an object and how can that change based upon its location? I am still missing something. Pud should really stay away from physics given that he doesn't even seem to understand even the basic units of measurement.
We often compare ourselves with NVDA, but it is INTEL that holds the greatest market share in graphics, and that is about to change in a big big way once ZEN is released.
FBP DATA at ESMO will be a big tipping point. We may see the Abstract data more than two weeks prior to actual conference on the 28th - Just like at ASCO - gale published the prelim FBP (1/15vg vs 11/22cg) data in late MAY and followed up with PR 2 weeks later.
The PPS jumped 20% in May as the news of the published data trickled out and then jumped up another 60% on the actual PR. Take a look at the chart.
We only will see the abstract posted early on the 10th, at ESMO if THEY are NOT Presenting. If we do not see the Abstract early they most likely will have the prestigious honor to have been selected to formally present. Think about that! So, Data on the 10th or the 28th huge catalyst.
Evidently you have that maneuver worked out .....Now we see how you operate.
Investors like to find points of interest regarding their search for profits and related info....just keeps us informed (if something happens to pop up that could give direction and interest regarding this investment). Doesn't hurt to look and seek info.
There is also nascent legislation moving through Congress to try to address the obesity problem in the U.S. Also today if you Google obesity there is an article that says there is weight gain after sleeve surgery. I think we are moving forward. It is just a lot slower than I suspected.